Source link : https://www.newshealth.biz/health-news/fda-expands-indication-for-amivantamab-in-lung-cancer/
The US Food and Drug Administration (FDA) has granted a second-line indication to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in non–small-cell lung cancer (NSCLC). Amivantamab with carboplatin and pemetrexed is now indicated for adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or […]
Author : News Health
Publish date : 2024-09-23 06:53:18
Copyright for syndicated content belongs to the linked Source.
Categories